ResMed Aktie News

Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 boom a lift, not a threat, to sales.

ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell

ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript

Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea.

Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

ResMed Inc. (RMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may a...

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA.